Global Peptide-based Cancer Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Class (Peptide Hormone Analogues, Peptide-Drug Conjugates, and Vaccines/Others), By Indication (Prostate & Breast, Neuroendocrine/GI, and Melanoma/Others), By Line of Therapy (2L/3L, 1L, and Adjuvant/Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Peptide-based Cancer Therapeutics Market Size Insights Forecasts to 2035

• The Global Peptide-Based Cancer Therapeutics Market Size Was Estimated at USD 26.5 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.44% from 2025 to 2035
• The Worldwide Peptide-Based Cancer Therapeutics Market Size is Expected to Reach USD 71.5 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Peptide-Based Cancer Therapeutics Market Size was worth around USD 26.5 Billion in 2024 and is predicted to Grow to around USD 71.5 Billion by 2035 with a compound annual growth rate (CAGR) of 9.44% from 2025 and 2035. The market for peptide-based cancer therapeutics presents numerous opportunities for growth, driven by the development of peptide drugs in cancer therapeutics, with the emergence of new production, modification, and analytical technologies.

Market Overview

The global peptide-based cancer therapeutics market refers to the pharmaceutical industry focused on using therapeutic peptides to treat cancer. There is an upsurge in the development of therapeutic peptides for a wide range of diseases, especially cancer. They are preferably used over antibiotics, radiation therapy, and chemotherapy owing to their flexibility, easy modification, low immunogenicity, and inexpensive production cost. Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and expanding partnerships. For instance, in January 2025, AbbVie announced that it had completed its acquisition of Nimble Therapeutics to strengthen AbbVie’s pipeline and R&D capabilities. Furthermore, the quick development of novel therapeutic vaccines by the use of the power of multi-epitope peptides is driving a huge surge in the global peptide-based cancer therapeutics market.    

Report Coverage

This research report categorizes the peptide-based cancer therapeutics market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the peptide-based cancer therapeutics market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the peptide-based cancer therapeutics market. 

Driving Factors

The growing burden of cancer, along with its increasing mortality rates, attributed to the ageing population, prevalence of unhealthy lifestyles and environmental changes, especially in the low- and middle-income countries, is responsible for driving the peptide-based cancer therapeutics market demand. Accounting for 20 million new cases of cancer, like non-melanoma skin cancer and about 9.7 million deaths. The emergence of new treatment modalities, including the combination of personalized peptide vaccines in combination with chemotherapy for cancers, is propelling the market growth. Furthermore, the technological advancements, including genetic engineering and innovative drug delivery systems, along with an R&D investment, are escalating the peptide-based cancer therapeutics market.     

Restraining Factors

The peptide-based cancer therapeutics market is restricted by the increased development costs, regulatory challenges. Further, varying treatment responses across the different patient populations are challenging the market growth.

Market Segmentation

The peptide-based cancer therapeutics market share is classified into class, indication, and line of therapy.   

• The peptide hormone analogues segment dominated the market with a major share of about 45% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the class, the peptide-based cancer therapeutics market is divided into peptide hormone analogues, peptide-drug conjugates, and vaccines/others. Among these, the peptide hormone analogues segment dominated the market with a major share of about 45% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Peptide based hormonal therapy is used for the treatment of breast and prostate cancers. Peptide based cancer vaccines present effective clinical data. Further, the emergence of combination therapy with conventional therapies, including radiation and chemotherapy, is propelling the market. For instance, GnRH (LHRH) receptor agonists are the most prescribed drugs in the class, and include goserelin and leuprolide, which are indicated for premenopausal patients and prostate cancer. 

• The prostate & breast segment accounted for a significant market share of about 39% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the indication, the peptide-based cancer therapeutics market is divided into prostate & breast, neuroendocrine/GI, and melanoma/others. Among these, the prostate & breast segment accounted for a significant market share of about 39% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Breast cancer is the leading cause of cancer-related fatalities in females, and there is increasing focus on peptide-based therapeutic strategies, including cell-penetrating peptides for breast cancer therapy. Further, its role in prostate cancer immunotherapy plays a vital role in prostate cancer treatment.

• The 2L/3L segment accounted for a major share of about 52% in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the line of therapy, the peptide-based cancer therapeutics market is divided into 2L/3L, 1L, and adjuvant/others. Among these, the 2L/3L segment accounted for a major share of about 52% in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Peptide-based drugs are used in targeted therapy as, alternative to conventional chemotherapy. For instance, the 6MHP vaccine that contains 6 melanoma-associated peptides to stimulate helper T cells, plus pembrolizumab, is safe, increases intratumoral lymphocytes, and induces T cell RSPS associated with prolonged OS.

Regional Segment Analysis of the Peptide-based Cancer Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the peptide-based cancer therapeutics market over the predicted timeframe.

North America is anticipated to hold the largest share of approximately 40-50% in the peptide-based cancer therapeutics market over the predicted timeframe. The market ecosystem in North America is strong, with both cutting-edge startups and major industrial heavyweights well-represented. For instance, in august 2025, Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA for the treatment of adult patients with extensive stage small cell lung cancer with disease progression on or after platinum based chemotherapy. The market for peptide-based cancer therapeutics has been driven by the expanding biopharma innovation hubs and R&D efforts. Further, the advancement in peptide discovery and drug design, with the rise in personalized medicine & precision therapeutics in oncology. The United States is dominating the North America peptide based cancer therapeutics market, accounting for nearly 82.1% share in 2024, driven by the advancement in peptide based drug development and the development of peptide-based vesicles for cancer immunotherapy.

Asia Pacific is expected to grow at a rapid CAGR of around 6.20% in the peptide-based cancer therapeutics market during the forecast period. The Asia Pacific area has a thriving market for peptide-based cancer therapeutics due to significant investment in R&D by the pharmaceutical industries. The region’s booming peptide production business is anticipated to promote market growth of peptide-based cancer therapeutics. For instance, in February 2025, India’s Granules made $22M play for Senn Chemicals to enter the peptides CDMO business. China is accounting for the dominant share of about 20-30% in the Asia Pacific peptide based cancer therapeutics market, owing to the expanding biopharma manufacturing, R&D efforts, and government support for peptide based drug development.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the peptide-based cancer therapeutics market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis AG
• Ipsen SA
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bristol Myers Squibb Company (BMS)
• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• Roche Holding AG
• Eli Lilly and Company
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In October 2025, Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, announced preliminary clinical and preclinical findings across its Helicon peptide pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.

• In April 2025, the WILEY Online Library published a review article on Peptide-Based Strategies in PLGA-enhanced tumor therapy.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the peptide-based cancer therapeutics market based on the below-mentioned segments: 

Global Peptide-based Cancer Therapeutics Market, By Class

• Peptide Hormone Analogues
• Peptide-Drug Conjugates
• Vaccines/Others

Global Peptide-based Cancer Therapeutics Market, By Indication

• Prostate & Breast
• Neuroendocrine/GI
• Melanoma/Others

Global Peptide-based Cancer Therapeutics Market, By Line of Therapy

• 2L/3L
• 1L
• Adjuvant/Others

Global Peptide-based Cancer Therapeutics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa